The USP8/PRSS35/CXCL2 axis inhibited CD8 + T-cell recruitment and immunotherapy response in HNSCC patients
This study identifies the USP8/PRSS35/CXCL2 axis as a critical mechanism of immune evasion in head and neck squamous cell carcinoma, where USP8 stabilizes PRSS35 to degrade the T-cell chemoattractant CXCL2, thereby suppressing CD8+ T-cell recruitment and suggesting that USP8 inhibition can synergize with anti-PD-1 immunotherapy to improve patient outcomes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is not just a mass of rogue cells; it is a complex ecosystem where the body's own defense forces are often tricked into standing down. In many cases, the immune system possesses powerful soldiers known as CD8+ T cells, which are trained to seek out and destroy malignant tissue. However, tumors can build invisible walls or release chemical signals that keep these soldiers at the gate, preventing them from entering the battlefield. This phenomenon, known as an immunosuppressive environment, is a major reason why modern cancer treatments called immune checkpoint blockers work for only a fraction of patients. These drugs are designed to remove the brakes on the immune system, but if the soldiers cannot reach the tumor in the first place, the treatment fails. Understanding how tumors hide from their natural enemies is the key to unlocking better cures for aggressive cancers like head and neck squamous cell carcinoma, a disease that affects the throat, mouth, and voice box.
Researchers at Loudi Central Hospital have uncovered a specific molecular pathway that allows these tumors to remain hidden. By studying patients who did not respond to standard immunotherapy, the team identified a protein called USP8 as a central figure in the tumor's defense strategy. In patients whose cancers continued to grow despite treatment, this protein was found in unusually high amounts. The scientists discovered that USP8 does not make the cancer cells grow faster on their own. Instead, it acts as a shield for the tumor by manipulating the chemical signals that usually call for help. It stabilizes another protein, PRSS35, which functions like a pair of molecular scissors. These scissors cut up a specific chemical messenger, CXCL2, that is normally released by the tumor to attract CD8+ T cells. By destroying this messenger, the tumor effectively silences the call for reinforcements, leaving the immune system blind to the cancer's presence.
To prove this mechanism, the researchers conducted a series of experiments using human cancer cells and mouse models. They first confirmed that patients with high levels of USP8 had significantly worse outcomes and were less likely to respond to immunotherapy than those with low levels. In the lab, when they reduced the amount of USP8 in cancer cells, the cells began to release higher levels of the CXCL2 messenger. This change alone was enough to draw more CD8+ T cells toward the cancer and increase their ability to kill the tumor cells. Crucially, the team showed that this effect was not because the cancer cells themselves were dying faster; the tumor cells grew at the same rate whether USP8 was present or not. The difference lay entirely in how the immune system interacted with the tumor. When the researchers blocked the receptor that CXCL2 uses to send its signal, the immune cells stopped migrating, proving that this specific chemical pathway was the linchpin of the process.
The study then moved to living animals to see if blocking this pathway could improve treatment results. Mice with head and neck tumors were treated with a drug that inhibits USP8, either alone or in combination with a standard immunotherapy drug that targets the PD-1 checkpoint. The results were striking. While the immunotherapy drug alone had a modest effect, and the USP8 inhibitor alone did not shrink the tumors significantly, the combination of both treatments caused the tumors to shrink dramatically. In these mice, the tumors were filled with a much higher number of active CD8+ T cells compared to the other groups. The researchers found that the USP8 inhibitor worked by restoring the levels of the CXCL2 messenger, which allowed the immune system to finally locate and attack the cancer. This suggests that the two drugs work together in a complementary way: one removes the brakes on the immune system, while the other opens the gate, allowing the soldiers to enter the fortress.
This work points to a new way of thinking about how to treat resistant cancers. The study establishes that the interaction between USP8, PRSS35, and CXCL2 is a critical driver of immune evasion in head and neck cancer. While the drug used in the experiments, PR-619, is a broad inhibitor that affects many proteins, the specific role of USP8 in this pathway offers a clear target for future, more precise medicines. The researchers also noted that measuring the levels of USP8 in a patient's tumor could help predict who would benefit most from this type of combination therapy. Although the study was conducted in mice and a limited number of human patients, the findings provide a solid foundation for developing strategies to overcome resistance in head and neck cancer. By understanding the specific molecular lock that keeps the immune system out, scientists can now work on creating the key to let it in.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.